Scholarlink

<p>Heart failure (HF) is a growing burden in sub-Saharan Africa, yet data on adherence to evidence-based medical therapy (EBMT) following the 2021 ESC/ACC guidelines remain scarce. This study explores patterns of EBMT prescriptions in a resource-limited African setting. We conducted a retrospective cohort study using medical records from patients hospitalised with acute HF at Laquintinie Hospital, Douala, Cameroon (2022–2024). The primary outcome was EBMT prescription at discharge, defined as at least Class IIa ESC/ACC recommendation irrespective of HF subtype and included medications like Renin-angiotensin aldosterone system (RAAS) inhibitors/Angiotensin Receptor–Neprilysin Inhibitors (ARNi), beta-blockers, mineralocorticoid receptor antagonists (MRAs), and sodium-glucose cotransporter-2 inhibitors (SGLT2i). Due to a limited sample size, analyses were primarily descriptive. Among 358 patients (median age 63&#xa0;years, 50.6% female), hypertensive heart disease was the leading HF aetiology (33.0%) and HFrEF predominated (n = 192, 53.6%). EBMT at discharge was prescribed in patients. EBMT appeared to increase over the years (0% in 2022, 1.9% in 2023 and 17.5% in 2024; χ<sup>2</sup> = 28.23, <i>p</i> &lt; 0.001) and vary by HF subtype: 5.7%, 14.3%, 11.8% and 0% in patients with HFrEF, HFmrEF, HFpEF and unclassified subtypes (χ<sup>2</sup> = 7.15, <i>p</i> = 0.067). Among patients with HFrEF, only 5.7% received quadruple therapy. Median hospital stay was 8&#xa0;days (IQR 6–12) and mortality rate was 11.7%, with no apparent difference based on EBMT prescription (<i>p</i> &gt; 0.05). EBMT use appeared to increase over time, but approximately nine in ten HF patients may be discharged without recommended medical therapies. Improving access to affordable to SGLT2 inhibitors and clinician education on updated guidelines could help address care gaps in resource-limited settings. Further research is needed to confirm these observations.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Evidence-based medical therapies for acute heart failure in Cameroon: a retrospective analysis of prescription patterns at Laquintinie Hospital, Douala, 2022–2024

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月1日

查看全文
  • Djibrilla Siddikatou,
  • Clovis Nkoke,
  • Sidick Mouliom,
  • Marie Solange Ndom,
  • Edgar Mandeng Ma Linwa,
  • Valérie Ndobo,
  • Hermann Tsague,
  • Sylvia Kotta,
  • Esther Éléonore Ngo Linwa,
  • Bronhilda Tifuh Takeh,
  • Ba Hamadou,
  • Félicité Kamdem,
  • Anastase Dzudie

摘要

Heart failure (HF) is a growing burden in sub-Saharan Africa, yet data on adherence to evidence-based medical therapy (EBMT) following the 2021 ESC/ACC guidelines remain scarce. This study explores patterns of EBMT prescriptions in a resource-limited African setting. We conducted a retrospective cohort study using medical records from patients hospitalised with acute HF at Laquintinie Hospital, Douala, Cameroon (2022–2024). The primary outcome was EBMT prescription at discharge, defined as at least Class IIa ESC/ACC recommendation irrespective of HF subtype and included medications like Renin-angiotensin aldosterone system (RAAS) inhibitors/Angiotensin Receptor–Neprilysin Inhibitors (ARNi), beta-blockers, mineralocorticoid receptor antagonists (MRAs), and sodium-glucose cotransporter-2 inhibitors (SGLT2i). Due to a limited sample size, analyses were primarily descriptive. Among 358 patients (median age 63 years, 50.6% female), hypertensive heart disease was the leading HF aetiology (33.0%) and HFrEF predominated (n = 192, 53.6%). EBMT at discharge was prescribed in patients. EBMT appeared to increase over the years (0% in 2022, 1.9% in 2023 and 17.5% in 2024; χ2 = 28.23, p < 0.001) and vary by HF subtype: 5.7%, 14.3%, 11.8% and 0% in patients with HFrEF, HFmrEF, HFpEF and unclassified subtypes (χ2 = 7.15, p = 0.067). Among patients with HFrEF, only 5.7% received quadruple therapy. Median hospital stay was 8 days (IQR 6–12) and mortality rate was 11.7%, with no apparent difference based on EBMT prescription (p > 0.05). EBMT use appeared to increase over time, but approximately nine in ten HF patients may be discharged without recommended medical therapies. Improving access to affordable to SGLT2 inhibitors and clinician education on updated guidelines could help address care gaps in resource-limited settings. Further research is needed to confirm these observations.